Learning Objectives

By the end of this chapter, learners will be able to:
1. Understand the basic principles of the complement system and its activation pathways.
2. Identify key complement-mediated kidney diseases and their distinct pathophysiological mechanisms.
3. Discuss the clinical presentation, diagnosis, and management of complement-mediated kidney diseases.
4. Recognize the role of complement biomarkers in diagnosis and monitoring.
5. Outline current and emerging therapeutic strategies targeting the complement system in renal diseases.

43.1 Introduction to the Complement System

The complement system is a crucial part of the innate immune system, consisting of a cascade of plasma proteins that, when activated, play a vital role in host defense against pathogens, clearance of immune complexes, and removal of apoptotic cells. However, dysregulation or uncontrolled activation of the complement system can lead to significant tissue damage, particularly in the kidneys, resulting in a range of complement-mediated kidney diseases.

There are three main pathways of complement activation:
– Classical Pathway: Initiated by antibody-antigen complexes or direct binding of C1q to pathogens.
– Lectin Pathway: Activated by the binding of mannose-binding lectin (MBL) to carbohydrate structures on microbial surfaces.
– Alternative Pathway: Continuously active at a low level (tick-over) and amplified on pathogen surfaces or altered host cells due to lack of regulatory proteins.

All three pathways converge at the activation of C3, leading to the formation of C3 convertases, which cleave C3 into C3a (anaphylatoxin) and C3b (opsonin). C3b then participates in the formation of C5 convertases, which cleave C5 into C5a (anaphylatoxin) and C5b. C5b initiates the formation of the Membrane Attack Complex (MAC, C5b-9), a pore-forming complex that causes cell lysis.

43.2 Key Complement-Mediated Kidney Diseases

Dysregulation of the complement system can lead to various kidney diseases, each with distinct features:

• C3 Glomerulopathy (C3G): A group of rare kidney diseases characterized by predominant C3 deposition in the glomeruli, with little or no immunoglobulin deposition. It includes:

  • Dense Deposit Disease (DDD): Characterized by highly electron-dense deposits within the glomerular basement membrane (GBM) on electron microscopy. Often associated with dysregulation of the alternative pathway, frequently due to C3 nephritic factor (C3NeF), an autoantibody that stabilizes C3 convertase.
  • C3 Glomerulonephritis (C3GN): Characterized by C3 deposits in the mesangium and/or subendothelial space, without the dense deposits seen in DDD. Also associated with alternative pathway dysregulation, often due to genetic mutations in complement regulatory proteins (e.g., Factor H, Factor I, MCP) or autoantibodies (e.g., C3NeF, Factor H autoantibodies).
  • Clinical Presentation: Highly variable, ranging from asymptomatic proteinuria/hematuria to nephritic syndrome, nephrotic syndrome, or rapidly progressive glomerulonephritis (RPGN). Often progressive to ESRD.

• Atypical Hemolytic Uremic Syndrome (aHUS): A rare, life-threatening genetic disorder characterized by uncontrolled activation of the alternative complement pathway, leading to thrombotic microangiopathy (TMA) primarily affecting the kidneys. It results from genetic mutations in complement regulatory proteins (e.g., Factor H, Factor I, MCP, C3, Factor B) or autoantibodies against Factor H.

  • Clinical Presentation: Acute onset of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Can be triggered by infections, pregnancy, or certain drugs.
  • Management: Eculizumab (a C5 inhibitor) has revolutionized treatment, preventing further TMA and improving renal outcomes.

• Immune Complex-Mediated Glomerulonephritis (e.g., Lupus Nephritis, Post-infectious GN): While primarily immune complex diseases, complement activation plays a significant role in their pathogenesis and tissue injury. For example, in lupus nephritis, immune complex deposition activates the classical pathway, leading to inflammation and damage.

43.3 Diagnosis and Management

Diagnosis of complement-mediated kidney diseases involves a combination of clinical suspicion, laboratory tests, and renal biopsy.

• Clinical Suspicion: Unexplained proteinuria, hematuria, AKI, or features of TMA.
• Laboratory Tests:
  • Complement Levels: Low C3 is common in C3G and some forms of aHUS. C4 may be normal or low depending on the pathway involved. CH50 (total hemolytic complement) assesses overall complement activity.
  • Complement Factor Assays: Measurement of Factor H, Factor I, Factor B, properdin levels.
  • Autoantibodies: C3NeF, Factor H autoantibodies, Factor I autoantibodies.
  • Genetic Testing: For mutations in complement regulatory genes (especially in aHUS and C3G).
  • Specific Markers for TMA: LDH, haptoglobin, schistocytes on blood smear, ADAMTS13 activity (to rule out TTP).
• Renal Biopsy: Essential for definitive diagnosis. Light microscopy, immunofluorescence (showing predominant C3 deposition in C3G), and electron microscopy (showing characteristic dense deposits in DDD or subendothelial/mesangial deposits in C3GN).

Management strategies vary depending on the specific disease:

• C3 Glomerulopathy: No universally approved treatment. Management often involves immunosuppression (corticosteroids, MMF, cyclophosphamide) to reduce inflammation and proteinuria. Complement-targeted therapies (e.g., eculizumab) are being explored, especially in severe or progressive cases.
• aHUS: Eculizumab is the cornerstone of treatment. Plasma exchange/infusion may be used as a bridge to eculizumab or in cases where eculizumab is not immediately available.
• Supportive Care: Blood pressure control, proteinuria reduction with ACE inhibitors/ARBs, management of CKD complications.

43.4 Role of Complement Biomarkers

Complement biomarkers are increasingly important for diagnosis, differential diagnosis, and monitoring disease activity and treatment response. These include:
– C3, C4 levels: Basic screening.
– Soluble C5b-9 (sC5b-9): Indicates terminal complement pathway activation.
– Factor H, Factor I, Factor B levels: To identify deficiencies.
– Autoantibodies: C3NeF, anti-Factor H.

43.5 Emerging Therapies

Research into complement-mediated kidney diseases is rapidly evolving, leading to the development of novel complement-targeted therapies. These include:
– C5 inhibitors (e.g., eculizumab, ravulizumab): Block the formation of MAC.
– C3 inhibitors: Prevent C3 cleavage and subsequent pathway activation.
– Factor B inhibitors: Block alternative pathway activation.
– Factor D inhibitors: Block alternative pathway activation.

These therapies offer hope for improved outcomes in patients with these challenging diseases.

Key Points on Complement-Mediated Kidney Diseases

1. Complement System: Innate immune cascade with classical, lectin, and alternative pathways, converging at C3 activation.
2. Key Diseases: C3 Glomerulopathy (DDD, C3GN) and Atypical Hemolytic Uremic Syndrome (aHUS) are primary complement-mediated renal diseases.
3. Pathophysiology: Uncontrolled complement activation, often due to genetic mutations or autoantibodies affecting regulatory proteins.
4. Diagnosis: Clinical presentation, complement levels (especially low C3), autoantibodies, genetic testing, and renal biopsy (predominant C3 deposition).
5. Management: Disease-specific (eculizumab for aHUS), immunosuppression for C3G, and supportive care.
6. Biomarkers: C3, C4, sC5b-9, complement factor levels, and autoantibodies aid in diagnosis and monitoring.
7. Emerging Therapies: Novel complement inhibitors targeting various points in the cascade.

Complement-Mediated Kidney Diseases Quick Guide

• Think Complement: Consider these diseases in unexplained AKI, TMA, or predominant C3 deposition on biopsy.
• Genetic Testing: Crucial for definitive diagnosis and guiding treatment in aHUS and C3G.
• Eculizumab: Game-changer for aHUS.
• Biomarkers: Use to assess complement activation and monitor therapy.

Diagnostic Pearls

1. Low C3, Normal C4: Strongly suggests alternative pathway activation, common in C3G and aHUS. If both C3 and C4 are low, consider classical pathway activation (e.g., lupus nephritis, cryoglobulinemia).
2. Schistocytes + AKI + Thrombocytopenia: Think TMA. Always rule out TTP (ADAMTS13 deficiency) before diagnosing aHUS.
3. Predominant C3 on Biopsy: If immunofluorescence shows strong C3 staining with minimal or no immunoglobulin, C3 Glomerulopathy is highly likely.

Management Pearls

4. Early Eculizumab in aHUS: Prompt administration of eculizumab is critical in aHUS to prevent irreversible kidney damage and improve outcomes.
5. Genetic Counseling: For patients with genetic forms of C3G or aHUS, genetic counseling is important for family members.
6. Infection Risk: Patients on complement inhibitors (e.g., eculizumab) are at increased risk of encapsulated bacterial infections, especially Neisseria meningitidis. Vaccination and prophylactic antibiotics are essential.

Patient Education Pearls

7. Chronic Nature: Educate patients about the chronic nature of these diseases and the importance of long-term follow-up and adherence to therapy.
8. Genetic Basis: Explain the genetic basis where applicable, and discuss implications for family screening.
9. Emergency Preparedness: For aHUS patients, ensure they understand the signs of relapse and when to seek urgent medical attention.

Complement Pathways Overview

Diagram illustrating the classical, lectin, and alternative pathways of complement activation.

Key Diagrams

• Pathophysiology of C3 Glomerulopathy: Illustration of C3 deposition patterns in DDD and C3GN.
• Thrombotic Microangiopathy in aHUS: Diagram showing endothelial damage, platelet aggregation, and microvascular thrombosis.
• Complement Cascade Regulation: Visual representation of key complement regulatory proteins and their sites of action.
• Mechanism of Action of Eculizumab: How C5 inhibition prevents MAC formation.

Question 1

Which of the following complement pathways is continuously active at a low level and amplified on pathogen surfaces?
A) Classical Pathway
B) Lectin Pathway
C) Alternative Pathway
D) Terminal Pathway

Answer: C) Alternative Pathway
Explanation: The alternative pathway is characterized by continuous low-level activation (tick-over) and amplification on activating surfaces.

Question 2

Dense Deposit Disease (DDD) is a subtype of C3 Glomerulopathy characterized by electron-dense deposits primarily within which glomerular structure?
A) Mesangium
B) Subendothelial space
C) Glomerular basement membrane (GBM)
D) Podocytes

Answer: C) Glomerular basement membrane (GBM)
Explanation: DDD is specifically defined by the presence of highly electron-dense deposits within the glomerular basement membrane on electron microscopy.

Question 3

Which of the following clinical features is characteristic of Atypical Hemolytic Uremic Syndrome (aHUS)?
A) Macroscopic hematuria and hypertension
B) Microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury
C) Heavy proteinuria and edema
D) Recurrent episodes of gross hematuria after infections

Answer: B) Microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury
Explanation: These three features form the classic triad of thrombotic microangiopathy, which is the hallmark of aHUS.

Question 4

In a patient with suspected C3 Glomerulopathy, which complement level is most commonly found to be low?
A) C1q
B) C4
C) C3
D) Factor B

Answer: C) C3
Explanation: C3 Glomerulopathy is characterized by predominant C3 deposition, and serum C3 levels are often low due to its consumption by uncontrolled alternative pathway activation.

Question 5

Which medication has revolutionized the treatment of Atypical Hemolytic Uremic Syndrome (aHUS) by inhibiting C5 activation?
A) Cyclophosphamide
B) Mycophenolate Mofetil
C) Eculizumab
D) Rituximab

Answer: C) Eculizumab
Explanation: Eculizumab is a monoclonal antibody that specifically targets C5, preventing the formation of the Membrane Attack Complex (MAC) and thereby halting the progression of aHUS.

Question 6

Patients receiving eculizumab for aHUS are at increased risk of infection with which type of bacteria?
A) Gram-positive cocci
B) Encapsulated bacteria, especially Neisseria meningitidis
C) Fungi
D) Viruses

Answer: B) Encapsulated bacteria, especially Neisseria meningitidis
Explanation: Eculizumab inhibits the terminal complement pathway, which is crucial for host defense against encapsulated bacteria. Vaccination against meningococcus and prophylactic antibiotics are recommended.

Question 7

Which of the following is a common autoantibody found in some patients with C3 Glomerulopathy that stabilizes C3 convertase?
A) Anti-dsDNA antibody
B) Anti-PLA2R antibody
C) C3 nephritic factor (C3NeF)
D) Anti-GBM antibody

Answer: C) C3 nephritic factor (C3NeF)
Explanation: C3NeF is an autoantibody that binds to and stabilizes the alternative pathway C3 convertase, leading to its prolonged activity and C3 consumption.

Question 8

Which diagnostic tool is essential for definitive diagnosis of C3 Glomerulopathy, showing predominant C3 deposition on immunofluorescence?
A) Urinalysis
B) Serum creatinine
C) Renal biopsy
D) Genetic testing

Answer: C) Renal biopsy
Explanation: Renal biopsy with immunofluorescence and electron microscopy is the gold standard for diagnosing C3 Glomerulopathy, revealing characteristic C3 deposition patterns.

Question 9

Uncontrolled activation of which complement pathway is primarily implicated in the pathogenesis of Atypical Hemolytic Uremic Syndrome (aHUS)?
A) Classical Pathway
B) Lectin Pathway
C) Alternative Pathway
D) Common Pathway

Answer: C) Alternative Pathway
Explanation: aHUS is characterized by dysregulation of the alternative complement pathway, often due to genetic defects in its regulatory proteins.

Question 10

Which of the following complement biomarkers indicates terminal complement pathway activation and can be used to monitor disease activity?
A) C3 levels
B) C4 levels
C) Soluble C5b-9 (sC5b-9)
D) Factor H levels

Answer: C) Soluble C5b-9 (sC5b-9)
Explanation: Soluble C5b-9 is a stable marker of terminal complement pathway activation and can be used to assess disease activity and response to complement-targeted therapies.

🎤 POWERPOINT PRESENTATION

[Link to interactive presentation slides covering all Complement-Mediated Kidney Diseases concepts with visual aids and animations]

Slide Outline:

1. Title Slide: Complement-Mediated Kidney Diseases – Understanding Pathogenesis and Targeted Therapies
2. Learning Objectives: What students will master
3. Introduction to Complement: Overview of pathways (Classical, Lectin, Alternative) and key components
4. C3 Glomerulopathy (C3G): Definition, Subtypes (DDD, C3GN), Pathophysiology
5. Atypical Hemolytic Uremic Syndrome (aHUS): Definition, Pathophysiology, Clinical Triad
6. Role of Complement in Other GN: Brief mention of immune complex GN (e.g., Lupus Nephritis)
7. Diagnostic Approach: Clinical Suspicion, Laboratory Tests (Complement Levels, Autoantibodies, Genetic Testing), Renal Biopsy
8. Management Strategies: C3G (Immunosuppression, Emerging Therapies), aHUS (Eculizumab)
9. Complement Biomarkers: Importance in Diagnosis and Monitoring (C3, C4, sC5b-9)
10. Emerging Therapies: Overview of novel complement inhibitors
11. Clinical Pearls: Diagnostic, Management, and Patient Education Tips
12. Summary: Key Takeaways for Complement-Mediated Kidney Diseases
13. Assessment: Quick review questions

This educational content is original material created for NephroHub, synthesizing established knowledge on Complement-Mediated Kidney Diseases while respecting all copyright considerations. All images are properly licensed or created specifically for educational use.

Visual Learning Workflow